Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Citação
ACTA HAEMATOLOGICA, v.127, n.1, p.56-59, 2012
Resumo
Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time of the suboptimal response in patient 1 and the failure in patient 2, we were able to detect the F359I mutation in the BCR-ABL tyrosine kinase domain using DNA sequencing in both patients. Therefore, it was decided to change the therapeutic regimen to dasatinib at a dose of 100 mg once daily in both patients. This change resulted in the achievement of complete cytogenetic remission in patient 1 after 4 months and a major molecular response within 2 and 3 months in both patients. Detection of the F359I mutation in our two cases likely explains the suboptimal response to imatinib in case 1 and the failure in case 2. This implies that in such cases dasatinib should be considered to effectively suppress the mutated clones.
Palavras-chave
BCR-ABL kinase, F359I point mutation, Kinase inhibitors, Suboptimal response
Referências
- Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200/JCO.2009.25.0779
- Baranska M, 2008, J APPL GENET, V49, P201, DOI 10.1007/BF03195613
- Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939
- DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902
- Deininger M, 2009, ASH ANN M NEW ORL, P462
- Faderl S, 1999, NEW ENGL J MED, V341, P164
- HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0
- Hughes T, 2006, BLOOD REV, V20, P29, DOI 10.1016/j.blre.2005.01.008
- Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092
- LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149
- O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936
- Okada M, 2011, INT J HEMATOL, V93, P243, DOI 10.1007/s12185-011-0769-z
- Quintas-Cardama A, 2009, CANCER, V115, P5382, DOI 10.1002/cncr.24601
- ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0
- Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034
- Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
- Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
- von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132
- Zeidan Amer, 2008, Clin Adv Hematol Oncol, V6, P673